Herceptin是近年來常見的抗乳癌藥物，其主要成份為trastuzumab。Trastuzumab是由DNA重組製成的人類單株抗體(Humanized Monoclonal Antibody，mAb)，具高度專一性地親和作用於細胞膜上的人類上皮生長因子接受器第二蛋白(Human Epidermal Growth Factor Receptor 2 Protein，HER2)，因而阻礙生長因子與HER2受體結合使細胞增生速度下降，此外，抗體亦能誘導殺手細胞（Killer cell）和巨噬細胞（Macrophage）殺死過度HER2表現的乳癌細胞，達到治療之目的。
本研究發展出新的鎝-99m標誌方式，並利用trastuzumab對HER2之專一性，將放射性核種鎝-99m(I)標誌於trastuzumab單株抗體，作為HER2過量表現乳癌細胞之造影劑。
利用無機化學合成方法製備的三羰基鎝化合物（[99mTc(CO)3(OH2)3]＋）為前驅物並將其標誌於抗體，得到99mTc(I)-trastuzumab，再利用高效能液相層析、分子大小排阻層析法、免疫反應分析與動物實驗來測試其標誌效率、產率、穩定度、對乳癌之活性及專一性。經實驗證明，99mTc(I)-trastuzumab在血清中相當穩定並且仍保有trastuzumab本身之專一性與活性；在生物分佈實驗中，亦發現99mTc(I)-trastuzumab與HER2親和之高度專一性。

Herceptin, the common anti-breast cancer medicine prevailed in recent years, contains mainly trastuzumab. Trastuzumab, the DNA recombinated humanized monoclonal antibody (mAb), can recognize specifically Human Epidermal Growth Factor Receptor 2 protein (HER2) on cell membrane. HER2 is a 185 kDa transmembrane receptor tyrosine kinase which is overexpressed in 25-30% of breast cancers. As HER2 is blocked by trastuzumab mAb, the growth factor will greatly reduce its binding with the receptor leading to lower the cell proliferation. Moreover, trastuzumab mAb will induce natural killer cells and macrophage to kill the cancer cells to cure breast cancer.
The study is to develop a novel 99m Tc labeled trastuzumab construct and via the high affinity of trastuzumab toward HER2 to adopt as an imaging agent for HER2 overexpressed breast cancer.
For the radiolabeling, the tricarbonyl techenium compound, [99mTc(CO)3(OH2)3]+, was synthesized and utilized as the precursor to conjugate rapidly with the monoclonal antibody, trastuzumab, by coordinating with N, O and S donors. The labeled mAb, 99mTc(I)-trastuzumab, was characterized by high performance liquid chromatography (HPLC) and size-exclusion chromatography (SEC) for its labeling yield and radiochemical purity. In addition, immunoreactivity assay and animal model experiment were undertaken to confirm its in vitro and in vivo stability, immunoreactivity and specific affinity with HER2 overexpressed cells.
In conclusion, 99mTc(I)-trastuzumab is stable in serum and retains the inherent property and immunoreactivity of trastuzumab. The result of biodistribution also reveals that 99mTc(I)-trastuzumab is of high affinity with HER2-positive BT-474 cells and related animal tumor, in constrast with much lower affinity with HER2-negative MCF-7 models.

1.Ralph Weissleder, Umar Mahmood. Molecular Imaging. Radiology 2001; 219:316–333

2.Tarik F.Massoud, Sanjiv S. Gambhir. Molecular imaging in living subjects:seeing fundamental biological processes in a new light. GENE DEV 2003; 17:545–580.

3.Seyed K. Imam. Molecular Nuclear Imaging：The Radiopharmaceuticals. CANCER BIOTHER RADIO 2005; 20:163-172

4.Thomas E. Witzig. Yttrium-90 Zevalin Radioimmunotherapy for Patients With Relapsed B-Cell Non-Hodgkin’s Lymphoma (IDEC-Y2B8) Witzig 2001:259-266

5.Michelle L. Hansman Whiteman, Aldo N. Serafini. 111In Octreotide Scintigraphy in the Evaluation of Head and Neck Lesions. AJNR 1997; 18:1073–1080

6.Nasim Khan, Noboru Oriuchi. Review of Fluorine-18-2–Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography (FDG-PET) in the Follow-Up of Medullary and Anaplastic Thyroid Carcinomas. Cancer Control 2005；12:254-260

7.Wei Chen, Timothy Cloughesy. Imaging Proliferation in Brain Tumors with 18F-FLT PET: Comparison with 18F-FDG. J Nucl Med 2005; 46:945–952

8.Murugesan Subbarayan, Urs O. Häfeli. A Simplified Method for Preparation of 99mTc-Annexin V and its Biologic Evaluation for InVivo Imaging of Apoptosis After Photodynamic Therapy. J Nucl Med 2003; 44:650–656

9.Naoki Tokita, Shinji Hasegawa. 99mTc-Hynic-annexin V imaging to evaluate inflammation and apoptosis in rats with autoimmune myocarditis. Eur J Nucl Med Mol Imaging. 2003; 30(2):232-8

10.Diane E. Milenic, Erik D. Brady. Antibody-Targeted Radiation Cancer Therapy. Nature Reviews 2004; 3:488-498

11.Olivier Couturier, Stephane Supiot. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med Mol Imaging. 2005；32:601-614

12.R.M. Neve, H. A. Lane, N.E. Hynes. The role of overexpressed HER2 in transformation. ANN ONCOL 2001; 12:S9-S13

13.Paivikki Kauraniemi, Sampsa Hautaniemi. Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines. Oncogene 2004; 23:1010–1013

14.J. Baselga. Clinical trials of Herceptin (trastuzumab). EUR J CANCER. 2001; 37:S18-S24

15.Charles A. Janeway, Paul Travers, Mark Walport, Mark Shlomchick. Immunobiology, the immune system in health and disease. 2005, 6th ed.

16.Kohler G. et al. Continuous Culture of Fused Cells Secreting Antibodies of Predefined Specificity. Nature 1975; 256:495

17.Paul Carter, Len Presta, Cornelia M. Gorman. Humanization of an antii-p185HER2 antibody for human cancer therapy. Pro. Natl Acad Sci 1992; 89:4285-4289

18.Rita Nahta, Francisco J. Esteva. Herceptin : mechanism of action and resistance. Cancer Letter 2006; 232:123-138

19.J. Baselga, J. Albanell. Mechanism of action of anti-HER2 monoclonal antibodies. ANN ONCOL 2001;12:S35-S41

20.Yoichi Nagata, Keng-Hsueh Lan. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6:117-127

21.R. M. Neve, H. A. Lane, N. E. Hynes. The role of overexpressed HER2 in transformation. ANN ONCOL 2001; 12: S9-S13

22.Brian Leyland Jones. Trastuzumab: hopes and realities. The LANCET ONCOL 2002; 3:137-144

23.Yasushi Arano. Recent advanced in 99mTc radiopharmaceuticals. ANN NUCL MED 2002; 16:79-93

24.Tove Olafsen, Vania E. Kenanova. Optimizing Radiolabeled Engineered Anti-p185HER2 Antibody Fragments for In vivo Imaging. Cancer Res 2005; 65:5907-5916

25.Anna Orlova, Fredrik Y. Nilsson. Comparative In Vivo Evaluation of Technetium and Iodine Labels on an Anti-HER2 Affibody for Single-Photon Imaging of HER2 Expression in Tumors. J NUCL MED 2006; 47:512-519

26.David Y. Zhang, Yong Li. Cytotoxicity of breast cancer cells overexpressing HER2/neu by 213Bi-Herceptin radioimmunoconjugate. CANCER LETT 2005; 218:181–190

27.Kayhan Garmestania, Diane E. Milenica. A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin. NUCL MED BIOL 2005; 29:599–606

28.Guiping Lia, Yongxian Wang. The experimental study on the radioimmunotherapy of the nasopharyngeal carcinoma overexpressing HER2/neu in nude mice model with intratumoral injection of 188Re-herceptin. NUCL MED BIOL 2005; 32:59–65

29.Åse M. Ballangrud, Wei-Hong Yang. Stig Palm. Alpha-Particle Emitting Atomic Generator (Actinium-225)-Labeled Trastuzumab (Herceptin) Targeting of Breast Cancer Spheroids: Efficacy versus HER2/neu Expression. CLIN CANCER RES 2004; 10:4489–4497

30.Paul E. Borchardt, Rui R. Yuan. Targeted Actinium-225 in Vivo Generators for Therapy of Ovarian Cancer1. CANCER RES 2003; 63:5084–5090

31.Daniel W. Mundy, Wael Harb, Tatjana Jevremovic. Radiation binary targeted therapy for HER-2 positive breast cancers: assumptions, theoretical assessment and future directions. Phys Med Biol 2006; 51:1377–1391

32.Roger Alberto, Roger Schibli. A Novel Organometallic Aqua Complex of Technetium for the Labeling of Biomolecules: Synthesis of [99mTc(OH2)3(CO)3]+ from [99mTcO4]- in Aqueous Solution and Its Reaction with a Bifunctional Ligand. J. Am. Chem. Soc. 1998; 120: 7987-7988

33.Gary L. Miessler, Donald A. Tarr. Inorganic Chemistry, 2nd ed. 1998

34.Roger Schibli, Rolf Schwarzbach. Steps toward High Specific Activity Labeling of Biomolecules for Therapeutic Application: Preparation of Precursor [188Re(H2O)3(CO)3]＋ and Synthesis of Tailor-Made Bifunctional Ligand Systems. Bioconjugate Chem 2002, 13, 750-756

35.Jonathan F. Tait, Christina Smith. Development of Annexin V Mutants Suitable for Labeling with Tc(I)-Carbonyl Complex. Bioconjugate Chem 2002, 13, 1119-1123

36.Klein P.H. Microbiology, Third edition, WCB Company, 1996, p117

37.Ying Tang, Deborah Scollard. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [99mTc]-HYNIC-trastuzumab (Herceptin) Fab fragments. NUCL MED COMMUN 2005; 26:427-432

38.Ying Tang, Judy Wang. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using 111In-trastuzumab (Herceptin) Fab fragments. NUCL MED BIOL 2005; 32: 51–58

39.Matthew K. Robinson, Mohan Doss. Quantitative Immuno-Positron Emission Tomography Imaging of HER2-Positive Tumor Xenografts with an Iodine-124 Labeled Anti-HER2 Diabody. Cancer Res 1471-1478

40.Michael R. McDevitt, Dangshe Ma. Design and synthesis of 225Ac radioimmunopharmaceuticals. APPL RADIAT ISOTOPES 2002; 57: 841–847

41.陳宛柔“三羰基鎝99m標誌HYNIC-cyclic RGD Peptide耦合物作為腫瘤造影劑之研究”清華大學碩士論文，2004.